Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 24th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 4/1/2025.
• Sold $1,001 – $15,000 in shares of W. R. Berkley (NYSE:WRB) on 4/1/2025.
• Sold $15,001 – $50,000 in shares of GoDaddy (NYSE:GDDY) on 4/1/2025.
• Purchased $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 3/31/2025.
• Purchased $1,001 – $15,000 in shares of Boeing (NYSE:BA) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Hologic (NASDAQ:HOLX) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/31/2025.

Supernus Pharmaceuticals Stock Down 5.1 %

SUPN stock opened at $30.64 on Wednesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 28.64 and a beta of 0.90. The business has a fifty day moving average of $34.09 and a two-hundred day moving average of $35.04.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SUPN. Barclays PLC grew its position in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Empowered Funds LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $1,498,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares in the last quarter.

Insiders Place Their Bets

In related news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 over the last 90 days. Corporate insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.